Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03193853
Title TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Baylor Research Institute
Indications

triple-receptor negative breast cancer

Therapies

Cisplatin + Nab-paclitaxel

MLN1117 + Sapanisertib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.